A systematic review of molecular and biological markers in tumours of the Ewing's sarcoma family

European Journal of Cancer

Volumn 39, Issue 1, 2003, Pages 19-30

  Riley, R D ^a   Burchill, S A ^b   Abrams, K R ^a   Heney, D ^a   Sutton, A J ^a   Jones, D R ^a   Lambert, P C ^a   Young, B ^a   Wailoo, A J ^c   Lewis, I J ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Ewing's Sarcoma; Meta analysis; Prognosis; Systematic review; Tumour marker

Indexed keywords

ACTIN; ALKALINE PHOSPHATASE; BETA ACTIN; BIOLOGICAL MARKER; CD45 ANTIGEN; CD57 ANTIGEN; CD99 ANTIGEN; CHROMOGRANIN; CHROMOGRANIN A; CHROMOGRANIN B; CYTOKERATIN; DESMIN; GLIAL FIBRILLARY ACIDIC PROTEIN; LACTATE DEHYDROGENASE; MOLECULAR MARKER; MUSCLE ANTIGEN; NERVE CELL ADHESION MOLECULE; NEURON SPECIFIC ENOLASE; PROTEIN MDM2; PROTEIN S100B; SYNAPTOPHYSIN; TUMOR MARKER;

CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER SURVIVAL; CHROMOSOME 10; CHROMOSOME 12; CHROMOSOME 13; CHROMOSOME 14; CHROMOSOME 15; CHROMOSOME 16; CHROMOSOME 17; CHROMOSOME 18; CHROMOSOME 19; CHROMOSOME 1Q; CHROMOSOME 2; CHROMOSOME 20; CHROMOSOME 21; CHROMOSOME 3; CHROMOSOME 4; CHROMOSOME 5; CHROMOSOME 6; CHROMOSOME 7; CHROMOSOME 8; CHROMOSOME 9; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE MARKER; EWING SARCOMA; GENE FUSION; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; META ANALYSIS; NEUROFILAMENT; ONCOGENE C MYC; PERIODIC ACID SCHIFF STAIN; PRIORITY JOURNAL; REVIEW;

EID: 0037213992     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)00500-2     Document Type: Article

References (30)

1. Cotterill S.J., Parker L., Malcolm A.J., Reid M., More L., Craft A.W. Incidence and survival for cancer in children and young adults in the North of England; a report from the Northern Region Young Persons' Malignant Disease Registry. Br. J. Cancer. 83:2000;397-403.
2. Triche, TJ. Pathology of pediatrics malignancies. In Pizzo, PA, Poplack, DG, eds. Principles and Practice of Paediatric Oncology, 2nd Edn. Philadelphia, JB Lipincott, 1993, 115-152 [chapter 7].
3. Aurias A., Rimbaut C., Buffe D., Dubousset J., Mazabraud A. Chromosomal translocations in Ewing's sarcoma. N. Eng. J. Med. 309:1983;496-497.
4. Turc-Carel C., Philip I., Berger M.P., Philip T., Lenoir G.M. Chromosomal translocations in Ewing's Sarcoma. N. Eng. J. Med. 309:1982;497-498.
5. Delattre O., Zucman J., Melot T.et al. The Ewing family of tumors - a subgroup of small-round-cell tumors defined by specific chimeric transcripts. New Eng. J. Med. 331:1994;294-299.
6. de Alava E., Gerald W.L. Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J. Clin. Oncol. 18:2000;204-213.
7. Craft A., Cotterill S., Malcolm A.et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's tumor study. J. Clin. Oncol. 16:1998;3628-3633.
8. Ahrens S., Hoffmann C., Jabar S.et al. Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: The CESS 86 experience. Med. Pediatr. Oncol. 32:1991;186-195.
9. Egger M., Davey Smith G., Altman D.G. Systematic Reviews in Health Care: Meta-Analysis in Context. 2001;BMJ Publishing Group, London.
10. Sutton A.J., Abrams K.R., Jones D.R., Sheldon T.A., Song F. Methods for Meta-analysis in Medical Research. 2000;John Wiley, London.
11. NHS Centre for Reviews and Dissemination. Undertaking Systematic Reviews of Research on Effectiveness. CRD Guidelines for Those Carrying Out or Commissioning Reviews. CRD Report 4. University of York, NHS Centre for Reviews and Dissemination, 1996.
12. Parmar M.K.B., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat. Med. 17:1998;2815-2834.
13. Cox D.R. Regression models and life tables (with discussion). J. Royal Stat. Soc. Series B. 34:1972;187-220.
14. Cox D.R. Partial likelihood. Biometrika. 62:1975;269-276.
15. Brereton H.D., Simon R., Pomeroy T.C. Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. Ann. Intern. Med. 83:1975;352-354.
16. Shimada H., Newton W.A., Soule E.H., Qualman S.J., Aoyama C., Maurer H.M. Pathologic features of extraosseous Ewing's sarcoma. a report from the Intergroup Rhabdomyosarcoma Study Hum. Pathol. 19:1998;442-453.
17. Brinkhuis M., Wijnaendts L.C., van der Linden J.C.et al. Peripheral primitive neuroectodermal tumour and extra-osseous Ewing's sarcoma; a histological, immunohistochemical and DNA flow cytometric study. Virchows. Archiv. 425:1995;611-616.
18. Shanfeld R.L., Edelman J., Willis J.E., Tuason L., Goldblum J.R. Immunohistochemical analysis of neural markers in peripheral primitive neuroectodermal tumors (pPNET) without light microscopic evidence of neural differentiation. Appl. Immunohistochem. 5:1997;78-86.
19. Kullendorff C.M., Mertens F., Donner M., Wiebe T., Akerman M., Mandahl N. Cytogenetic aberrations in Ewing sarcoma: are secondary changes associated with clinical outcome? Med. Pediatr. Oncol. 32:1999;79-83.
20. Sainati L., Leszl A., Montaldi A., Ninfo V., Basso G. Is the deletion of the short arm of chromosome 1 a prognostic factor in pediatric peripheral primitive neuroepithelioma (PNET)? [letter]. Med. Pediatr. Oncol. 26:1996;143-144.
21. Zoubek A., Dockhorn-Dworniczak B., Delattre O.et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. 14:1996;1245-1251.
22. Zoubek A., Ladenstein R., Windhager R.et al. Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR. a preliminary evaluation Int. J. Cancer. 79:1998;56-60.
23. de Alava E., Kawai A., Healey J.H.et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. 16:1998;1248-1255.
24. Huijgen H.J., Sanders G.T., Koster R.W., Vreeken J., Bossuyt P.M. The clinical value of lactate dehydrogenase in serum: a quantitative review. Eur. J. Clin. Chem. Clin. Biochem. 35:1997;569-579.
25. Altman D.G. Systematic reviews of studies of prognostic variables. Egger M., Davey Smith G., Altman D.G. Systematic Reviews in Health Care: Meta-Analysis in Context. 2001;228-247 BMJ Publishing Group, London. [Chapter 13].
26. Sakamoto J., Teramukai S., Koike A., Saji S., Ohashi Y., Nakazato H. Prognostic value of preoperative immunosuppressive acidic protein in patients with gastric carcinoma. Findings from three independent clinical trials. Tumor Marker Committee for the Study Group of Immunochemotherapy with PSK for Gastric Cancer. Cancer. 77:1996;2206-2212.
27. Altman D.G., Lyman G.H. Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res. Treat. 52:1998;289-303.
28. Altman D.G., De Stavola B.L., Love S.B., Stepniewska K.A. Review of survival analyses published in cancer journals. Br. J. Cancer. 72:1995;511-518.
29. Hutchon D.J.R. Publishing raw data and real time statistical analysis on e-journals. Br. Med. J. 222:2001;530.
30. Eiser C., Hill J.J., Vance Y.H. Examining the psychological consequences of surviving childhood cancer. systematic review as a research method in pediatric oncology J. Pediatr. Psychol. 25:2000;449-460.